CCL20 and lymphoma: MIP3α-antigen fusion DNA vaccine constructs have shown efficacy in a prophylactic melanoma model against gp100 [33], a therapeutic lymphoma model against oncofetal antigen (OFA) [31], and a prophylactic malaria model against circumsporozoite protein (CSP) [30].